<DOC>
	<DOCNO>NCT00676949</DOCNO>
	<brief_summary>The purpose study evaluate clinical safety efficacy cyclophosphamide combine cancer specific epitope peptide cocktail advanced/relapsed solid tumor include GI/lung/cervical cancer</brief_summary>
	<brief_title>Safety Study Cancer Specific Epitope Peptides Cocktail Cervical , GI , Lung Tumors</brief_title>
	<detailed_description>KOC1 , TTK , CO16 ( URLC10 ) , DEPDC1 , MPHOSPH1 identify use genome-wide expression profile analysis use cDNA microarray previous study . The investigator determine HLA-A*2402 restrict epitope peptide respectively derive KOC1 , TTK , CO16 ( URLC10 ) , DEPDC1 , MPHOSPH1 show strong INF-gamma production stimulate appropriate target express appropriate protein HLA-A*2402 . Furthermore , vaccinate peptide , specific CTLs determine vaccination . Therefore investigator focus prevention expansion solid tumor highly express 5 protein use 5 peptide .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>clinical diagnosis unresectable relapsed gastrointestinal , lung cervical cancer patient performance status 01 age 20 80 least 4 week previous therapy life expectancy 3 month permissible bone marrow , liver renal function HLAA2402 viral hepatitis , HIV HTLV1 severe underlie disease pregnant lactate woman active brain metastasis uncontrollable infection systemic corticosteroid immune suppressant treatment history allergy epitope peptide IFA</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>epitope peptide</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>interleukin-2</keyword>
</DOC>